Organization
Shizuoka Cancer Center, Nagaizumi, Japan
9 abstracts
Abstract
Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.Org: The University of Tokyo, Tokyo, Japan, National Cancer Center Hospital Japan East, Kashiwa, Japan, Sapporo Medical University Hospital, Sapporo-Shi, Japan, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, Shizuoka Cancer Center, Nagaizumi, Japan,
Abstract
Prognostic and predictive value of ctDNA-based MRD and actionable biomarkers in patients with resectable colorectal cancer: CIRCULATE-Japan GALAXY.Org: National Cancer Center Hospital East, Kashiwa, Japan, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan, The Committee of Hereditary Colorectal Cancer of the Japanese Society for Cancer of the Colon and Rectum, Sendai City Medical Center Sendai Open Hospital, Hyogo Medical University,
Abstract
Associations between early tumor shrinkage (ETS)/depth of response (DpR) and overall and post-progression survivals (OS/PPS) from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.Org: National Cancer Center Hospital East, Kashiwa, Japan, Shizuoka Cancer Center, Nagaizumi, Japan, Kyushu University, University of Nantes Medical School, University Medical Center Utrecht,
Abstract
Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.Org: Shizuoka Cancer Center, Nagaizumi, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Kyushu University, University of Nantes Medical School Nantes, University Medical Center Utrecht,
Abstract
Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.Org: Kanagawa Cardiovascular and Respiratory Center, National Cancer Center Hospital East, Kashiwa, Japan, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Department of Data Sciences, Internal Medicine III, Wakayama Medical University,
Abstract
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.Org: Kurume University Hospital, Kanagawa Cancer Center, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, National Hospital Organization Kinki-Chuo Medical Center, Osaka International Cancer Institute, Osaka, Japan,
Abstract
Development of a postoperative nomogram to predict disease-specific mortality in gastric cancer: A competing risk analysis using variables the AJCC recommends be collected and registered.Org: Shizuoka Cancer Center, Nagaizumi, Japan, Division of Gastric Surgery, Department of Quantitative Health Sciences, The Cleveland Clinic Foundation, Cleveland Clinic Brunswick Urgent Care,
Abstract
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, Cancer Institute of the State of São Paulo, São Paulo, Brazil, São Paulo, Brazil, Brazil,
Abstract
Effect of lymph node dissection and adjuvant therapy in patients with sentinel node+ melanoma: An observational multicenter study.Org: National Cancer Center Hospital East, Kashiwa, Japan, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan Association for Development of Community Medicine, Nagoya University Graduate School of Medicine, Aichi Cancer Center Hospital,